This week, Amplia CEO and Managing Director Dr. Chris Burns, spoke with Andrew Musgrave of ASX briefs to discuss Amplia's innovative work targeting focal adhesion kinase (FAK), a protein overexpressed in many solid tumors and fibrotic diseases.
Have a listen:
